Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Down 2.2%

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) shares were down 2.2% during mid-day trading on Friday . The company traded as low as $1.23 and last traded at $1.36. Approximately 82,971 shares changed hands during mid-day trading, a decline of 32% from the average daily volume of 122,215 shares. The stock had previously closed at $1.39.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright decreased their price target on shares of Enlivex Therapeutics from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, June 11th.

Enlivex Therapeutics Price Performance

The firm has a market cap of $28.38 million, a PE ratio of -0.98 and a beta of 0.98. The business’s fifty day moving average is $1.38 and its 200-day moving average is $2.31.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings results on Friday, June 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. Analysts forecast that Enlivex Therapeutics Ltd. will post -0.81 EPS for the current year.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.